Antiangiogenic Isoforms of Vascular Endothelial Growth Factor Predominate in Subretinal Fluid of Patients With Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

Ricker, Lukas J. A. G.; Dieudonné, S.C.; Kessels, Alfons G.H.; Rennel, Emma; Berendschot, Tos T. J. M.; Hendrikse, Fred; Kijlstra, Aize; Heij, Ellen C. La

doi:10.1097/iae.0b013e31821800b9

Cited by 20 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The paradox of increased VEGF levels in an avascular process like PVR can be explained by observations by Ricker et al[24] and Perrinet al[25] which showed that antiangiogenic isoforms of VEGF (so-called VEGF xxx b) account for the majority of the total VEGF. These isoforms are products of splicing in the C-terminal exon and inhibit proliferative and vasodilator effects of VEGF 165 .…”

Section: Discussionmentioning

confidence: 99%

Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: A randomized pilot study

Tousi

Hasanpour

Soheilian

2016

J Ophthalmic Vis Res

View full text Add to dashboard Cite

Purpose:To evaluate the effect of intravitreal bevacizumab (IVB) as a surgical adjunct in prevention of proliferative vitreoretinopathy (PVR) after retinal detachment surgery.Methods:In this controlled, randomized pilot study, 27 patients with primary retinal detachment undergoing pars plana deep vitrectomy were included. Of these, 12 received IVB at the end of procedure. The anatomic success and best corrected visual acuity (BCVA) were compared to the control group at months 3 and 6 postoperatively.Results:At three month follow-up, 3 of 11 eyes (27.3%) had detached retinas in the IVB group versus 6 of 12 (50.0%) in the control group (P = 0.40). At six-month follow-up, 3 of 10 eyes (30%) had detached retinas in the IVB group versus 3 in 8 (37.5%) in the control group (P > 0.99). Mean logMAR BCVA improved significantly in both groups relative to baseline, but did not show a significant difference at three-and six-month follow-ups between the two groups.Conclusion:Our preliminary results show neither a benefit nor any harm from intervention in both anatomic and visual outcomes. Our results support conducting additional studies to evaluate the effect of intravitreal bevacizumab on postoperative PVR.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: A randomized pilot study

Tousi

Hasanpour

Soheilian

2016

J Ophthalmic Vis Res

View full text Add to dashboard Cite

show abstract

“…As these structures form, they may physically attach to the retina, contract, and cause retinal tears. Support for this hypothesis stems from the presence of many growth factors and cytokines in the pathological vitreous or epiretinal membrane, including platelet-derived growth factor (PDGF) isoforms [21, 22], hepatocyte growth factor (HGF) [22, 23], vascular endothelial growth factor (VEGF) [24], epidermal growth factor (EGF) [25], pigment epithelium-derived factor (PEDF) [26], transforming growth factor β (TGF β ) [27, 28], tumor necrosis factor α (TNF α ) [29, 30], TNF β [29], granulocyte colony-stimulating factor (G-CSF) [29], fibroblast growth factors (FGF) [29, 31], basic fibroblast growth factor (bFGF) [32], insulin [25], insulin-like growth factor-1 (IGF-1) [33], connective tissue growth factor (CTGF) [22, 23], glutamine synthetase [32], interleukin 1 (IL-1) [34], IL-6 [29, 31], IL-8 [29, 35], IL-10 [29], interferon γ (IFN γ ) [28, 29], monocyte chemotactic protein [35, 36], macrophage-colony stimulating factor [35], granulocyte colony-stimulating factor (G-CSF) [29], chemokine ligand 2 (CCL2) [29], CCL3 [29], CCL4 [29], CCL5 [29], and protein [31]. …”

Section: The Growth Factor and Cytokine Hypothesis For Developmentmentioning

confidence: 99%

Mechanisms of Inflammation in Proliferative Vitreoretinopathy: From Bench to Bedside

Moysidis

Thanos

Vavvas

2012

Mediators of Inflammation

104

View full text Add to dashboard Cite

Proliferative vitreoretinopathy (PVR) is a vision-threatening disease and a common complication of surgery to correct rhegmatogenous retinal detachment (RRD). Several models of the pathogenesis of this disease have been described with some of these models focusing on the role of inflammatory cells and other models focusing on the role of growth factors and cytokines in the vitreous which come into contact with intraretinal and retinal pigment epithelial cells. New experiments have shed light on the pathogenesis of PVR and offer promising avenues for clinical intervention before PVR develops. One such target is the indirect pathway of activation of platelet-derived growth factor receptor alpha (PDGRα), which plays an important role in PVR. Clinical trials assessing the efficacy of 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH), daunorubicin, and 13-cis-retinoic acid, among other therapies, have yielded mixed results. Here we review inflammatory and other mechanisms involved in the pathogenesis of PVR, we highlight important clinical trials, and we discuss how findings at the bench have the potential to be translated to the bedside.

show abstract

“…VEGF levels were found to be higher in subretinal fluid and vitreous fluid samples of PVR compared with uncomplicated RRD. [9][10][11][12][13] Considering the role of VEGF in the pathogenesis of PVR, it is rational to consider anti-VEGF medications as a potential modality for prevention of PVR.…”

Section: Introductionmentioning

confidence: 99%

Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy

Falavarjani

Hashemi

Modarres

et al. 2014

Eye

View full text Add to dashboard Cite

Purpose To evaluate the role of bevacizumab injected into the silicone oil at the end of retinal reattachment surgery for rhegmatogenous retinal detachment (RRD) associated with severe proliferative vitreoretinopathy (PVR) for prevention of postoperative PVR and compare the results with those without intrasilicone injection. Methods In this prospective comparative interventional study, eyes with RRD with grade C PVR were included. Standard 20 gauge pars plana vitrectomy, and retinal reattachment was performed. In case group, 1.25 mg bevacizumab was injected into the silicone oil at the end of surgery. The rate of retinal redetachment associated with PVR was assessed.

show abstract

Antiangiogenic Isoforms of Vascular Endothelial Growth Factor Predominate in Subretinal Fluid of Patients With Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

Cited by 20 publications

References 26 publications

Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: A randomized pilot study

Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: A randomized pilot study

Mechanisms of Inflammation in Proliferative Vitreoretinopathy: From Bench to Bedside

Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy

Contact Info

Product

Resources

About